



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/991,971	11/26/2001	Markku Ahotupa	2630-113	8814

6449 7590 03/24/2003

ROTHWELL, FIGG, ERNST & MANBECK, P.C.
1425 K STREET, N.W.
SUITE 800
WASHINGTON, DC 20005

EXAMINER

HUYNH, PHUONG N

ART UNIT PAPER NUMBER

1644

DATE MAILED: 03/24/2003

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/991,971	AHOTUPA ET AL.	
	Examiner	Art Unit	
	" Neon" Phuong Huynh	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE One MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on _____.
- 2a) ☐ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-16 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1644

DETAILED ACTION

1. The location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1644, Group 1640, Technology Center 1600.
2. Claims 1-16 are pending.

Election/Restrictions

3. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - (1). Claims 1-6, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
 - (2). Claims 1-2 and 4-6, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
 - (3). Claims 1-2 and 5-6, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
 - (4). Claims 1 and 3-4, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone**, classified in Class 424, subclass 195.1 and Class 424, subclass 195.1 and Class 514, subclass 22.
 - (5). Claims 1 and 3, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (6). Claims 1 and 4, drawn to a method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **a mixture of hydroxymatairesinol, matairesinol and enterolactone**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (7). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the ischemia-reperfusion injury is **myocardial infarction, or stroke**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (8). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (9). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, Class 424, subclass 195.1 and Class 514, subclass 22.
- (10). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (11). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (12). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the ischemia-reperfusion injury is **myocardial infarction**, or stroke, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (13). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (14). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, Class 424, subclass 195.1 and Class 514, subclass 22.
- (15). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (16). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (17). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **a mixture of hydroxymatairesinol and matairesinol** wherein the ischemia-reperfusion injury is **myocardial infarction, or stroke**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (18). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (19). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (20). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (21). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (22). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the ischemia-reperfusion injury is **myocardial infarction**, or **stroke**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (23). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (24). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (25). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (26). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (27). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone** wherein the ischemia-reperfusion injury is **myocardial infarction**, or stroke, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (28). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (29). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (30). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (31). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and enterolactone** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (32). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, matairesinol and enterolactone** wherein the ischemia-reperfusion injury is **myocardial infarction**, or stroke, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (33). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, matairesinol and enterolactone** wherein the ischemia-reperfusion injury is **transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (34). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, matairesinol and enterolactone** wherein the ischemia-reperfusion injury is **adult respiratory distress syndrome**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (35). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, matairesinol and enterolactone** wherein the ischemia-reperfusion injury is **ischemic heart disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (36). Claims 7-10, drawn to a method of treating or preventing an **acute ischemia-reperfusion injury** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, matairesinol and enterolactone** wherein the ischemia-reperfusion injury is **endotoxic or hemorrhagic shock**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (37). Claims 7-8, 11-13 and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (38). Claims 7-8, 11-13 and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **an inflammatory condition such as inflammatory bowel disease and Crohn's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (39). Claims 7-8, and 11-15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **an inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (40). Claims 7-8, 11-13 and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (41). Claims 7-8, 11-13, and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (42). Claims 7-8, 11-13 and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (43). Claims 7-8, 11-13, and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (44). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is an **autoimmune disease such as type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (45). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is an **autoimmune disease such as type II diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (46). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (47). Claims 7-8, 11-13 and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **cataract**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (48). Claims 7-8, 11-13 and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **amyotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (49). Claims 7-8, 11-13 and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (50). Claims 7-8, 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (51). Claims 7-8, 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (52). Claims 7-8 and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **hydroxymatairesinol** wherein the chronic condition is **osteoporosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (53). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (54). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory bowel disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (55). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (56). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (57). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (58). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (59). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (60). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is an **autoimmune disease such as type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (61). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is an **autoimmune disease such as type II diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (62). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (63). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **cataract**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (64). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **amyotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (65). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (66). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (67). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **matairesinol** wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (68). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (69). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory bowel disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (70). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (71). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (72). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (73). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (74). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (75). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is an **autoimmune disease such as type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (76). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is an **autoimmune disease such as type II diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (77). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (78). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **cataract**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (79). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **amyotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (80). Claims 7-8, and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (81). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (82). Claims 7-8, and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol and matairesinol** wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (83). Claims 7-8, 11-13, and 15 drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (84). Claims 7-8, 11-13, and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is an **inflammatory condition such as inflammatory bowel disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (85). Claims 7-8, 11-13, and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is an **inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (86). Claims 7-8, 11-13, and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (87). Claims 7-8, 11-13, and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (88). Claims 7-8, 11-13, and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (89). Claims 7-8, 11-13, and 15-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (90). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is an **autoimmune disease such as type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (91). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is an **autoimmune disease such as type II diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (92). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (93). Claims 7-8, 11-13 and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **cataract**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (94). Claims 7-8, 11-13, and 15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **amyotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (95). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 93.1.
- (96). Claims 7-8, and 11-15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (97). Claims 7-8, and 11-15, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a mixture of **enterolactone** and hydroxymatairesinol wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- 98). Claims 7-8, and 11-16, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is **enterolactone** wherein the chronic condition is **osteoporosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (99). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (100). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory bowel disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (101). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is an **inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (101). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 93.1.
- (102). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (103). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (104). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- 105). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is an **autoimmune disease such as type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (106). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is an **autoimmune disease such as type II diabetes**, classified in Class 424, subclass 93.1.
- (107). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (108). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **cataract**, classified in Class 424, subclass 93.1.
- (109). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **amyotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (110). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- 111). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (112). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of enterolactone and hydroxymatairesinol** wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (113). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **asthma**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (114). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is an **inflammatory condition such as inflammatory bowel disease**, classified in Class 424, subclass 93.1.
- (115). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is an **inflammatory condition such as inflammatory condition of the skin**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

- (116). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **HIV or AIDS**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (117). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **psoriasis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (118). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **Parkinson's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (119). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **Alzheimer's disease**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (120). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is an autoimmune disease such as **type I diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (121). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is an autoimmune disease such as **type II diabetes**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

- (122). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **hypercholesterolemic atherosclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (123). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **cataract**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (124). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **amylotrophic lateral sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (125). Claims 7-8 and 11-13, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **autoimmune rheumatoid arthritis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (126). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is a **rejection reaction due to tissue transplantation**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.
- (127). Claims 7-8 and 11-14, drawn to a method of treating or preventing a **chronic condition** caused by overactivity of phagocytes or lymphocytes in an individual by administering a lignan wherein the lignan is a **mixture of hydroxymatairesinol, enterolactone, and enterolactone** wherein the chronic condition is **autoimmune multiple sclerosis**, classified in Class 424, subclass 195.1 and Class 514, subclass 22.

Art Unit: 1644

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups (1-127) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the methods of treating different diseases that differ with respect to their etiology using distinct products that differ with their respect to their structures and effects differ with respect to their process steps and treatment endpoints. Therefore, they are patentably distinct.

4. Because these inventions are distinct for the reasons given above and the searches are not co-extensive, restriction for examination purposes as indicated is proper.
5. Due to the complexity of the claimed invention an oral restriction was not made.
6. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Huynh "NEON" whose telephone number is (703) 308-4844. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Art Unit: 1644

8. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phuong N. Huynh, Ph.D.

Patent Examiner

Technology Center 1600

March 24, 2003

Phillip Gambel
PHILLIP GAMBEL, PH.D.
PRIMARY EXAMINER
TC 1600
3/24/03